

**WEDNESDAY, 17<sup>th</sup> OCTOBER 2012 COMMENCING 10.30 AM**

**(UNTIL 4.00 PM APPROX)**

**AT THE CATRIN FINCH CENTRE, GLYNDWR UNIVERSITY**

**WREXHAM LL11 2AW**

### **AGENDA**

- |  |                                   |
|--|-----------------------------------|
| 1. <b>Welcome and introduction</b>   | <b>Enclosure</b>                  |
| 2. <b>Apologies</b>  |                                   |
| 3. <b>Declarations of interest</b>   |                                   |
| 4. <b>Chairman's report (verbal update)</b>  |                                   |
| 5. <b>Minutes of previous meeting</b>  | 1/AWMSG/1012                      |
| 6. <b>Appraisal 1: Full Submission</b><br><b>Paliperidone palmitate (Xeplion<sup>®</sup>)</b> prolonged release suspension for injection for the maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed | 2/AWMSG/1012<br><b>Appendices</b> |
| 7. <b>Appraisal 2: Full Submission</b><br><b>Eslicarbazepine acetate (Zebinix<sup>®</sup>)</b> as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation   | 3/AWMSG/1012<br><b>Appendices</b> |
| 8. <b>Appraisal 3: Full Submission</b><br><b>Colecalciferol (Fultium-D<sub>3</sub><sup>®</sup>)</b> for the prevention and treatment of vitamin D deficiency and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.<br>Fultium-D <sub>3</sub> <sup>®</sup> is indicated in adults, the elderly and adolescents  | 4/AWMSG/1012<br><b>Appendices</b> |
| 9. <b>Appraisal 4: Limited Submission</b><br><b>Bupivacaine hydrochloride/fentanyl (Bufyl<sup>®</sup>)</b> for maintaining analgesia post-operatively and for maintaining epidural analgesia during labour   | 5/AWMSG/1012<br><b>Appendices</b> |
| 10. <b>Appraisal 5: Limited Submission</b><br><b>Ramipril oral solution</b> for the treatment of hypertension, reduction of cardiovascular morbidity and mortality, treatment of renal disease, treatment of symptomatic heart failure and secondary prevention after acute myocardial infarction  | 6/AWMSG/1012<br><b>Appendices</b> |

- |     |  |                     |
|-----|--|---------------------|
| 11. | <b>All Wales advice on the role of oral anticoagulants for the prevention of stroke and systemic embolism in people with atrial fibrillation</b> | <b>7/AWMSG/1012</b> |
| 12. | <b>Low molecular weight heparins (LMWH) in pregnancy</b>   | <b>8/AWMSG/1012</b> |
| 13. | <b>All Wales In-Patient Medication Administration Record Charts</b>  | <b>9/AWMSG/1012</b> |

**Date of next meeting:**

**Wednesday, 14<sup>th</sup> November 2012 in Abergavenny**